Breakthrough progress has been made in the research and development of innovative drugs for Hong Kong stocks and platinum pharmaceuticals. Nona Biotech, a subsidiary of Platinum Pharmaceuticals, recently announced that it has signed an exclusive licensing agreement with Pfizer for the global clinical development and commercialization of antibody conjugated drug (ADC) HBM9033 targeting human cortisol (MSLN).
According to the agreement, Nona Bio will receive a prepayment of $53 million and recent payments, as well as a milestone payment of up to $1.05 billion. In addition, Nona Bio is also eligible to receive a tiered royalty fee from its net sales.
And the Chairman of the Board of Directors of Platinum Pharmaceuticals Wang Jinsong, Chairman of Nona Biology, stated: We are pleased to have partnered with Pfizer, a global leader dedicated to developing targeted drugs for cancer patients. This marks a significant milestone in the development of our proprietary Harbour Mice® platform and ADC ecosystem, recognizing Nona Biotech's strong capabilities and expertise in antibody discovery and development. Through innovative models, this collaboration has effectively strengthened Nona's global collaboration network and further expanded it The scientific and commercial value of our technology platform
It is reported that Nona Biotechnology is an international innovative biotechnology company. As a wholly-owned subsidiary of Hopkin Pharmaceuticals, the company is committed to cutting-edge technological innovation and provides partners with complete I to ITM (Idea to IND) services covering target validation and diverse forms of drug molecules from discovery to preclinical research and development. By utilizing an integrated and innovative technology platform and a globally leading team of scientists, the company provides a complete antibody discovery solution covering antigen preparation, animal immunity, single B cell screening, antibody development and engineering, drug efficacy evaluation, and pharmacological evaluation.
The breakthrough of platinum pharmaceutical innovative drugs in the international market has once again focused the market's attention on the company's sustained profitability.
Regarding this, Wang Jinsong said in an interview with the Shanghai Stock Exchange News reporter: As an 18A company and an innovative pharmaceutical company that has not yet commercialized its products, the company still focuses on cutting-edge innovation, which definitely requires continuous investment. With the further maturity of the entire business, the demand for global innovation, and the corresponding business revenue generated through various means and platforms, we achieved our first-ever profit in the first half of this year, which is a very significant benefit for the company For us, we must further invest in cutting-edge innovation and continuously enhance the company's profitability through diversified methods such as BD cooperation, building on our current research and development capabilities
Wang Jinsong further stated that the company's innovative drug research and development is not for the sake of BD. "Every product we are currently promoting is aimed at whether it has clinical value from beginning to end. In this process, the stage of the innovative drug project and the type of partner we choose are determined based on the characteristics of each project."